Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · United Therapeutics (UTHR)

United Therapeutics Q3 revenue rises 7% to $799.5 million; net income up 10%

Positive Impact 3 of 5 earnings Written later

United Therapeutics reported record third-quarter 2025 results, with total revenues up 7% year over year to $799.5 million and net income up 10% to $338.7 million. Diluted earnings per share rose 12% to $7.16, and the company said Tyvaso DPI growth drove the increase.

Key points

  • Total revenues of $799.5 million for the quarter ended September 30, 2025, compared with $748.9 million a year earlier.
  • Diluted earnings per share of $7.16, compared with $6.39 in the third quarter of 2024, up 12%.
  • Tyvaso DPI net product sales rose 22% to $336.2 million, while Nebulized Tyvaso sales fell 11% to $141.8 million.

The filing

CompanyUnited Therapeutics (UTHR)
Form8-K, current report
Filed with the SECOct 29, 2025, 6:34 AM ET
Accession number0001082554-25-000036

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.